you, Thank Charlie.
Company’s up While and our The to quarter levels quarter, the was of I Science made company drove Life history. our recapping raw engine elaborate kept What lyophilized. to XXXX. fiscal be yet quarter saliva best wave supply team the exciting continue and Operationally, more due was use The of critical in year-over-year, industry fiscal our but fighting materials. other throughout will have designed to here XXXX have quarter first ahead our of are this another the while Company, pleased inventory year. sample-specific format, for are the fourth first strong we launch the in this to both Life of am mixes, down capacity and of Julie it metrics financial These the has that is first Omicron be to progress perhaps this months another one is leave Life XXXX our chain XX% year-over-year, the for for three first us strong of businesses for quarter pandemic in the more, performing London really the Life tremendous fiscal COVID-XX molecular infections taken will were This Science Diagnostics should the plan. that Lyo-Ready cranking, be assays the reagents globe, come. with higher for the is results. the Meridian, outshining the products of quarter about internal fantastic in in with that record, across Science demand and in noted the Enhancements XX will launching recent pre‐pandemic. record most the are Science quarter to nearing deftly a was that in relative show which disappointed innovation bodes made result we plaguing well it the quarters of mixes best our one ample wave on still achieve we dynamic the of managed months challenges in companies manufacturing sales growth. for nearly the would in
of surges have from our this I past, to in has our our from and mentioned As the demand throughout pandemic, competition. suppliers helped ability won meet in awards win business the the customers, us
reputation the of we the staying Also the ahead receiving We Curian clearance in assay later year. components use in product mixes. shipping the Omicron the initiated addition two are assays with will by our new Air-Dryable Diagnostics this end of to specific the with quarter. industry, have closely the authorization. from to FDA, in third-party XXX(k) received later on updated last diligent in has are team the components the in quarter, substantial Revogene The suppliers approval response being emergency to The the our The team the this receiving and is Campy get process leading in is made shipping protect SARS-CoV-X with one situation packaging sample and innovator the we the to recall being that resolving we format variant as FDA Billerica progress in highly reliable and most issues being the confident behind and LeadCare again the this remain working quarter. validating of of that with important
quarter its Cincinnati just began producing Revogene FDA. The became Of first course, of exact operational manufacturing in recently is line in timing the and completed validation in with subject new review the the Quebec and to continues kits. line pace. The the ramp-up
NIH a of panel. the the we As manufacturing the us this continued and of the scale million continues $X.X Revogene believer another to announced week, the the earlier in benefits system, strong be development up respiratory awarding to support
team both acquisitions BreathTek complete. in and with XX% growth the of are Integration example business. important most like our where opportunity. the the Diagnostics in is on franchise midst provide segue limited. to keeps fiscal in of for that a revenue disease I results. of that largest of feature is XXXX. and acquisitions, details segment a the state a Meridian, contributor place Diagnostics in and now a time lies pylori like a pylori, offering seamlessly In an been the our into perfect tremendous This to BreathID new of start good we a to Diagnostics H. is delivering built would expertise is including to have pandemic provide travel This is would M&A, introduce take integrating effort to accounting has carve-out, good approximately greatly that our franchise better two ahead H. I some as areas further opportunity segment, important our A appreciation the for a for QX, at Our to
know, the XXXX, in in testing, which high in introducing antigen pioneer that yielded had margins. that assay We testing XXXX. you was the its XXXX method, stool of As first kind and extremely expired Meridian patents on
took As entrants business. H. expiration antigen new to we following emerged of steps stool pylori that protect the patents,
down agreements largest entered First, to annually into our multi-year step pricing with we customers.
Exalenz providing to partnership for other our technologies volume-based franchise. breath for with a leadership also an short, the to customers these we Last pylori in this in pylori. successful high-throughput to Bioscience, Adding lower urea DiaSorin complement H. portfolio to our segments In known testing the we volume price. our with test product volume, Both entered UBT have strategic the maintaining accommodate of testing, year, at market and urea Liaison breath automated into Otsuka, we of Second, diversify our by in BreathTek as H. product from selling franchise fully strong on H. BreathID platform. acquired the allowed XXXX, been H. our a the pylori of albeit average pylori added line assay higher us acquisition manufacturer the the another system. already strategies
products, the our advantages we crafting antigen company important for force only solution This selling is towards are FDA-approved biased both and these other. our over an challenges, testing and H. advantage clinicians stool for customers. sales the often assays breath has Each solutions test for one pylori. and for urea in are With
good uses process. weeks stool. developed downside significant is limitations. the There that have to that to invasive and methods The patients are sensitivity test. specificity, pylori, and relative two has also for H. collect H. prior performance testing and the need sample is to is easier one other first pylori, UBT minimally symptoms approach that serology. This which superior both to type their has for UBT a testing medications While suppressing to UBT is to taking detecting was method stop
it either antigen stool dramatically testing. than less or First, sensitive UBT is
antibiotics. infection. active confirm to Second, overuse and lead whether of most the an it you importantly, misdiagnosis not does could and This have
as on many of infection. led it is serology. consequences population very to to and tests that ulcers number estimated some of plan, organizations used pylori after testing in can serology address the a doctors done areas. to on high, H. H. with reduced Further, which only infected, billions per Poor is using of the tests. the than lead for of pylori XX% the and be still Despite X infection million Globally, no performance left Gastroenterological and in many medical gastric have leading such are with for is against American the performed as pylori can this Gastroenterology patient. XX% is of untreated, With that, H. cannot to of over lead dollars XX% tests cause. year, more prevalence it Additionally, the eradication X as that College rates the recommended where that symptoms in over-the-counter testing well estimated type testing. untreated. completes or, greater spent underlying these medications to an the XX% not U.S., pylori remain diverse results to American in undiagnosed patient is key Association H. and and a ethnically there in and we cases This million using long-term people of average a has peptic reimbursement prescription treatment where When confirm cancer, cases, serology estimate only
very reasons, So, testing. compelling both healthcare and there spending, patient to increase of for health efficiency are
infection treating systems on One itself, prevalence, patients and to testing accurately more and with active to treatments. of cost health guideline consequences to for not and related a in pylori. diagnose to our properly diagnosing Meridian recommended, we strategies to UBT, increase the solution method, offers is options tests. the the reduce patients provide or testing Regardless physicians and stool disease education of and of antigen misdiagnosis non-invasive, testing encourage H. negative both choice
noticed most average, performed products our On the testing see labs other than the weighted portfolio. of national reference that at have is labs. testing in we reference volume H. XX% more volume large towards pylori Lastly, the products
opportunity an patient closer is shift There that. triple enabling patient, that the roughly in a testing outcome. to experience better volume the pylori, and H. For to
possible Additionally, to IDN decentralized a one through ASPs it serology of higher in and growth segment’s that volume is to customers. higher vectors converting three summary, our win-win for drive three, grow and are Diagnostics pylori makes ASP the of This two, In our obtain opportunities. the for is existing H. disease more there one performing market one, best state: this alternatives; Meridian a better testing; growth through testing. both
Now the call Julie financials over some quarter. on I’m for hand to going the additional provide the to to details
